Jubilant Pharmova Ltd.
Fundamentals
- Market cap
- ₹15,361 cr
- P/E
- 38.55×
- ROE
- 13.42%
- Debt / equity
- 0.39
- Div yield
- 0.51%
- 52-week range
- 786.05 — 1248.00
Jubilant Pharmova Ltd.
Latest quarter · Mar 2026
Strength & growth
The timeline — 10 notes on Jubilant Pharmova Ltd.
June 2026
- 30 Jun 26 · 6:48 PM IST Brief Brief · Mid cap
Jubilant Pharmova's ₹53.37 cr tax setback
Income tax rectification order disallows brought-forward losses at subsidiary Jubilant Biosys, but the company says it will appeal and sees no material impact.
- 24 Jun 26 · 4:49 PM IST Brief Brief · Mid cap
Jubilant Pharmova's ₹107.89 cr tax demand cut to ₹42.41 cr
Rectification order restores ₹65.48 cr in tax losses for subsidiary Jubilant Generics, but the company continues to appeal the remaining amount on merits.
- 19 Jun 26 · 1:08 AM IST Brief Brief · Mid cap
Jubilant Pharmova's Spokane plant gets 8 FDA observations, none on sterility
No sterility concerns at key injectables unit, but 8 observations require a 15-day response. Spokane Line 3 expansion is the growth driver.
May 2026
- 29 May 26 · 9:53 PM IST Alert Alert · Mid cap
USFDA hits Jubilant's Montreal plant with a Warning Letter
The FDA found prior remediation efforts insufficient, escalating the site from 'Official Action Indicated' status. New drug approvals from the facility are now frozen.
- 22 May 26 · 7:43 PM IST Brief Brief · Order Wins · Mid cap
Jubilant Pharmova subsidiary lands ₹107.89 cr tax demand
A transfer pricing order for FY23 hits the subsidiary, forcing a ₹37.70 cr write-down of deferred tax assets.
- 22 May 26 · 7:01 PM IST Brief Brief · Concalls · Mid cap
Jubilant Pharmova pulls Spokane Line 3 timeline forward by two years
The company expects peak revenue of $80-90M sooner than planned, while the Montreal plant continues to burn cash until FY28.
- 22 May 26 · 2:54 PM IST Brief Brief · Earnings · Mid cap
Jubilant Pharmova posts ₹8,280 cr revenue, adds oncology client to Montreal facility
FY26 revenue grew 14% while EBITDA rose 8%. The CDMO unit added a global oncology product and is remediating its Montreal plant.
- 22 May 26 · 2:41 PM IST Brief Brief · Mid cap
Jubilant Pharmova names Ashish Mukkirwar as CFO
Arun Kumar Sharma steps down into an advisory role as the company works through regulatory hurdles at its Montreal facility.
- 22 May 26 · 2:32 PM IST Brief Brief · Earnings · Mid cap
Jubilant Pharmova profit halves to ₹3,975 m on Montreal remediation costs
Revenue grew 14.5% to ₹82,796 million, but net profit fell 52% as the company absorbed ₹535 million in costs to fix its Montreal facility.
- 22 May 26 · 2:27 PM IST Brief Brief · Earnings · Mid cap
Jubilant Pharmova profits halved to ₹397 cr as remediation costs weigh
Regulatory challenges at the Montreal site drag on bottom-line performance despite 14.5% revenue growth.